Proactive Investors - Run By Investors For Investors

Morgan Stanley doesn’t think there’s much money to be made by investing in GSK

GSK is in the middle of some big changes: it is bedding in a multi-billion-dollar acquisition; rebuilding its drugs pipeline; and merging its consumer healthcare division with one of its rivals
gsk logo
There’s a lot of work going on behind the scenes at GSK right now

GlaxoSmithKline PLC (LON:GSK) is “very much a work in progress” according to Morgan Stanley, and analysts at the US investment bank aren’t convinced there is much money to be made by investing in the drugmaker right now.

The number crunchers have resumed their coverage of GSK with an ‘underweight’’ recommendation – essentially advising punters to limit the amount of stock they hold in their portfolio.

READ: GSK gets green light for asthma treatment

That’s alongside a price target of 1,520p, slightly below where the shares currently find themselves.

Unsurprisingly, GSK was down 0.3% to 1,579p in early-afternoon trading on Monday.

Much of Morgan Stanley’s cautiousness stems from the fact that GSK is going through some big changes at the moment.

The FTSE 100 group is in the process of bedding in Tesaro, which it recently bought for more than US$5bn to help grow its presence in the lucrative cancer space.

That is part of a wider plan to rebuild its pipeline, which has slipped behind many of its rivals in recent years.

Pound could also dent performance

Although the tie-up gives GSK “greater critical mass” in cancer, the analysts noted that “commercial risk in oncology will remain high”, while there are also long-term challenges associated with building an innovative pipeline.

The drugs giant is also about to hive off its consumer health business, which includes brands such as Sensodyne and Nicorette, after striking a joint venture deal with US rival Pfizer Inc (NYSE:PFE).

Morgan Stanley argues that this integration will have to go well to paper over short-term pressures in GSK’s HIV arm, which is seeing a drop in prices and new treatment start share.

Compounding the difficulties is the Great British pound, which the chin scratchers expect will head up to US$1.45 over the next 18 months, hitting dollar-denominated sales somewhat.

View full GSK profile View Profile

GlaxoSmithKline PLC Timeline

Related Articles

consumer health segment overview
January 11 2019
The company sells clinically validated anti-ageing products for hair, skin and body.
scientist in laboratory
May 24 2019
Here we take a closer look at healthcare investor NetScientific PLC (LON:NSCI)
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use